Nanjing Genscript Biotech Co., Ltd.

Nanjing Legend Biotech Co., Ltd.

Zhongdao Li

Zhenyu Liu

Chuan-Chu Chou

Shu Wu

Yafeng Zhang

Wang Zhang

Liusong Yin

Zhuo Fang

Tielin Zhou

Fangliang Zhang

Dongliang Wang

Lixin Song

The present invention relates to an anti-CD47/anti-PD-1 bispecific antibody, preparation method thereof and use thereof. The bispecific antibody includes (a) a first antigen binding portion including a heavy chain variable region (Vn) and a light chain variable region (Vl), wherein Vn and Vl form an antigen binding site that specifically binds to CD47; and (b) a second antigen binding portion including a single-domain antibody (sdAb) that specifically binds to PD-1, wherein the first antigen binding portion and the second antigen binding portion are fused with each other. The bispecific antibody of the present invention can block two manners of tumor immune escape simultaneously, and thus, has a good effect in tumor immunotherapy.

Anti-CD47/anti-PD-1 bispecific antibody, preparation method and use thereof

Provided is a fusion protein dimer using an antibody Fc region as the backbone, comprising a first and a second polypeptide chain. The first polypeptide chain comprises a first antibody Fc region and one or more single-domain antibodies fused to the first antibody Fc region. The second polypeptide chain comprises a second antibody Fc region and one or more single domain antibodies fused to the second antibody Fc region. The first polypeptide chain and/or the second polypeptide chain further comprise a cytokine fused to the Fc region of the respective antibody. Further provided is use of the fusion protein dimer in preparing an immunotherapeutic drug for treating tumors. The Fc fusion protein heterodimer not only increases the activity of a single domain antibody, but also significantly improves the biological activity of a cytokine. Further, by means of the targeting specificity of the antibody, the targeted transport of the cytokine is effectively enhanced, and cytotoxicity is attenuated, thereby obtaining better anti-tumor potential.

Fusion protein dimer using antibody Fc region as backbone and use thereof

Disclosed herein are multispecific, such as bispecific, antigen binding proteins comprising a first antigen binding domain comprising a heavy chain variable domain and a light chain variable domain, and a second antigen binding domain comprising a single-domain antibody. Pharmaceutical compositions comprising the multispecific antigen binding proteins, kits and methods of use thereof are further provided.

Multispecific antigen binding proteins and methods of use thereof

Growing community of inventors

Nanjing, China

Zhongdao Li